Summary
20.97 -0.52(-2.43%)09/27/2024
Corbus Pharmaceuticals Holdings Inc (CRBP)
Corbus Pharmaceuticals Holdings Inc (CRBP)
Key Facts
1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
-2.76 | 7.04 | -63.35 | -52.23 | -41.04 | 230.22 | -86.02 | -76.70 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Trading Data | ||
Close | 20.97 | |
Open | 21.23 | |
High | 22.20 | |
Low | 20.80 | |
Volume | 944,441 | |
Change | -0.60 | |
Change % | -2.76 | |
Avg Volume (20 Days) | 1,506,934 | |
Volume/Avg Volume (20 Days) Ratio | 0.63 | |
52 Week Range | 3.03 - 61.90 | |
Price vs 52 Week High | -66.12% | |
Price vs 52 Week Low | 592.04% | |
Range | -1.23 | |
Gap Up/Down | -2.10 |
Fundamentals | ||
Market Capitalization (Mln) | 259 | |
EBIDTA | -36,784,140 | |
PE Ratio | 0.0000 | |
PEG Ratio | 0.0000 | |
WallStreet Target Price | 68.00 | |
Book Value | 9.2280 | |
Earnings Per Share | -10.3100 | |
EPS Estimate Current Quarter | -1.0900 | |
EPS Estimate Next Quarter | -1.2000 | |
EPS Estimate Current Year | -5.8600 | |
EPS Estimate Next Year | -5.8000 | |
Diluted EPS (TTM) | -10.3100 | |
Revenues | ||
Profit Marging | 0.0000 | |
Operating Marging (TTM) | 0.0000 | |
Return on asset (TTM) | -0.2636 | |
Return on equity (TTM) | -0.5952 | |
Revenue TTM | 0 | |
Revenue per share TTM | 0.0000 | |
Quarterly Revenue Growth (YOY) | -1.0000 | |
Quarterly Earnings Growth (YOY) | 0.0000 | |
Gross Profit (TTM) | -16,136,826 |
Dividends | ||
Dividend Share | 0.0000 | |
Dividend Yield | ||
Valuations | ||
Trailing PE | 0.0000 | |
Forward PE | 0.0000 | |
Price Sales (TTM) | 0.0000 | |
Price Book (MRQ) | 1,490.7854 | |
Revenue Enterprise Value | 8.2564 | |
EBITDA Enterprise Value | -9.6587 | |
Shares | ||
Shares Outstanding | 10,507,200 | |
Shares Float | 6,776,432 | |
Shares Short | 0 | |
Shares Short (Prior Month) | 0 | |
Shares Ratio | 0.00 | |
Short Outstanding (%) | 0.00 | |
Short Float (%) | 0.08 | |
Insider (%) | 0.68 | |
Institutions (%) | 63.49 |
09/26 08:00 EST - globenewswire.com
Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit
NORWOOD, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the Company will participate in BMO Capital Markets' Oncology Summit, to be held October 8, 2024 in New York, NY. Dr. Dominic Smethurst, MA MRCP, Chief Medical Officer of Corbus, will participate in a panel titled Capitalizing on Validated Mechanism in Oncology. Dr. Smethurst will also be joined by Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, to participate in one-on-one investor meetings.
Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit
NORWOOD, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the Company will participate in BMO Capital Markets' Oncology Summit, to be held October 8, 2024 in New York, NY. Dr. Dominic Smethurst, MA MRCP, Chief Medical Officer of Corbus, will participate in a panel titled Capitalizing on Validated Mechanism in Oncology. Dr. Smethurst will also be joined by Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, to participate in one-on-one investor meetings.
09/23 14:01 EST - benzinga.com
Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now
Corbus Pharmaceuticals Holdings, Inc. CRBP received reaffirmed buy ratings from both H.C. Wainwright and Oppenheimer this week, with analysts citing the company's diversified pipeline as a key driver for future growth, despite a sharp stock decline after Novo Nordisk‘s NVO mid-stage data on its obesity drug.
Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now
Corbus Pharmaceuticals Holdings, Inc. CRBP received reaffirmed buy ratings from both H.C. Wainwright and Oppenheimer this week, with analysts citing the company's diversified pipeline as a key driver for future growth, despite a sharp stock decline after Novo Nordisk‘s NVO mid-stage data on its obesity drug.
09/08 07:43 EST - 247wallst.com
3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry.
3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry.
08/26 12:00 EST - marketwatch.com
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders stand to capture up to 20% of the lucrative market, Jefferies analysts said in a research note Monday.
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders stand to capture up to 20% of the lucrative market, Jefferies analysts said in a research note Monday.
08/26 10:55 EST - zacks.com
Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 43.8% in Corbus Pharmaceuticals (CRBP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 43.8% in Corbus Pharmaceuticals (CRBP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
08/20 08:00 EST - globenewswire.com
Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung
NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee.
Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung
NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee.
08/09 13:01 EST - zacks.com
Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why
Corbus Pharmaceuticals (CRBP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why
Corbus Pharmaceuticals (CRBP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
08/09 10:55 EST - zacks.com
Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade
The consensus price target hints at a 54.2% upside potential for Corbus Pharmaceuticals (CRBP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade
The consensus price target hints at a 54.2% upside potential for Corbus Pharmaceuticals (CRBP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
08/06 08:00 EST - globenewswire.com
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
NORWOOD, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today provided a corporate update and reported financial results for the quarter ended June 30, 2024.
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
NORWOOD, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today provided a corporate update and reported financial results for the quarter ended June 30, 2024.
07/30 08:50 EST - globenewswire.com
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August
NORWOOD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in two investor conferences during the month of August. Dr. Cohen will provide a corporate update and participate in one-on-one investor meetings at the following events.
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August
NORWOOD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in two investor conferences during the month of August. Dr. Cohen will provide a corporate update and participate in one-on-one investor meetings at the following events.
06/30 10:13 EST - investorplace.com
Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn't Discovered Yet
Prospects for interest rate cuts are fueling speculations about which small-cap stocks will be winners when they hit. Because smaller companies don't have the same financial access as larger stocks, they are forced to borrow money at higher cost, which impacts their ability to grow.
Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn't Discovered Yet
Prospects for interest rate cuts are fueling speculations about which small-cap stocks will be winners when they hit. Because smaller companies don't have the same financial access as larger stocks, they are forced to borrow money at higher cost, which impacts their ability to grow.
06/03 13:03 EST - seekingalpha.com
Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025
Corbus Pharmaceuticals Holdings, Inc. reported positive results achieved in phase 1 China study, using CRB-701 for patients with mUC and cervical cancer; 44% and 43% ORR achieved for each, respectively. The global urothelial carcinoma market is expected to reach $6.82 billion in 2032. It is expected that the global cervical cancer treatment market could reach $12.63 billion by 2030.
Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025
Corbus Pharmaceuticals Holdings, Inc. reported positive results achieved in phase 1 China study, using CRB-701 for patients with mUC and cervical cancer; 44% and 43% ORR achieved for each, respectively. The global urothelial carcinoma market is expected to reach $6.82 billion in 2032. It is expected that the global cervical cancer treatment market could reach $12.63 billion by 2030.
06/01 10:00 EST - globenewswire.com
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
NORWOOD, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), announced today, that the Poster [#296] Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate , has been presented at American Society of Clinical Oncology (ASCO) Annual Conference by Dr. Jian Zhang, Chief Physician (Oncology), Deputy Director of Administration, Clinical director of Phase 1 Centre, Fudan University Shanghai Cancer Center.
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
NORWOOD, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), announced today, that the Poster [#296] Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate , has been presented at American Society of Clinical Oncology (ASCO) Annual Conference by Dr. Jian Zhang, Chief Physician (Oncology), Deputy Director of Administration, Clinical director of Phase 1 Centre, Fudan University Shanghai Cancer Center.
05/30 08:00 EST - globenewswire.com
Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
NORWOOD, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the 45th Annual Goldman Sachs Global Healthcare Conference to be held June 10-13, 2024 in Miami Beach, FL.
Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
NORWOOD, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the 45th Annual Goldman Sachs Global Healthcare Conference to be held June 10-13, 2024 in Miami Beach, FL.
05/23 17:05 EST - globenewswire.com
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that the abstract [No. 3151] for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting being held from May 31-June 4, 2024 in Chicago has been released. The ASCO abstract is titled: Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate and will be presented as a poster [#296] on June 1, 2024 from 9:00 AM -12:00 PM by Dr. Jian Zhang, Fudan University Shanghai Cancer Center.
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that the abstract [No. 3151] for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting being held from May 31-June 4, 2024 in Chicago has been released. The ASCO abstract is titled: Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate and will be presented as a poster [#296] on June 1, 2024 from 9:00 AM -12:00 PM by Dr. Jian Zhang, Fudan University Shanghai Cancer Center.
05/09 08:00 EST - globenewswire.com
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2024 RBC Capital Markets Global Healthcare Conference to be held May 14-15, 2024 in New York, NY.
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2024 RBC Capital Markets Global Healthcare Conference to be held May 14-15, 2024 in New York, NY.
05/07 08:00 EST - globenewswire.com
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
NORWOOD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended March 31, 2024.
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
NORWOOD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended March 31, 2024.
05/01 08:00 EST - globenewswire.com
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
NORWOOD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion as part of the BTIG Obesity Health Forum, to be held virtually on May 8, 2024.
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
NORWOOD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion as part of the BTIG Obesity Health Forum, to be held virtually on May 8, 2024.
04/24 16:05 EST - globenewswire.com
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
NORWOOD, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that an abstract providing updated data from the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 (SYS6002) has been accepted for presentation at the 2024 American Society of Clinical Oncology annual meeting, to be held May 31-June 4, 2024 in Chicago, IL. CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4 with a third generation, site-specific cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Encouraging safety and efficacy data from this trial were presented at ASCO-GU 2024.
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
NORWOOD, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that an abstract providing updated data from the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 (SYS6002) has been accepted for presentation at the 2024 American Society of Clinical Oncology annual meeting, to be held May 31-June 4, 2024 in Chicago, IL. CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4 with a third generation, site-specific cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Encouraging safety and efficacy data from this trial were presented at ASCO-GU 2024.
04/19 14:30 EST - investorplace.com
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
Small-cap stocks tend to outperform their larger brethren over time. After several years of underperformance, it looked like the little guys were going to start winning again.
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
Small-cap stocks tend to outperform their larger brethren over time. After several years of underperformance, it looked like the little guys were going to start winning again.